To evaluate the efficacy of switching from intravitreal ranibizumab to intravitreal aflibercept in choroidal neovascularization secondary to angioid streaks.
Design:
Multicenter retrospective interventional case series.
Methods:
Patients previously treated with intravitreal ranibizumab with at least 12-month follow-up (M12) after switching (M0) to intravitreal aflibercept. Switch to intravitreal aflibercept was decided in cases of refractory or recurrent choroidal neovascularization. Primary endpoint: Change of best-corrected visual acuity using the Early Treatment Diabetic Retinopathy Study letters. Secondary endpoints: Mean change of central macular thickness, absence of intraretinal/subretinal fluid on spectral domain optical coherence tomography and the percentage of eyes with absence of leakage on fluorescein angiography.
Results:
Fourteen eyes of 13 patients were included. Mean best-corrected visual acuity was 65.0 ± 21.03 letters at M0 and 63.5 ± 17.30 letters at M12 (p = 0.5). Secondary endpoints: Mean central macular thickness was 344 ± 194.65 µm at M0 and 268 ± 79.97 µm at M12 (p = 0.008). Absence of intraretinal/subretinal fluid was observed in 71%. Fluorescein angiography (nine eyes) showed absence of leakage in 77% (seven eyes).
Conclusion:
Switching from intravitreal ranibizumab to intravitreal aflibercept represents a therapeutic option in patients with refractory or recurrent choroidal neovascularization secondary to angioid streaks.
Charbel IssaPFingerRPGottingC, et al. Centrifugal fundus abnormalities in pseudo-xanthoma elasticum. Ophthalmology2010; 117(7): 1406–1414.
4.
AessoposAFarmakisDLoukopoulosD.Elastic tissue abnormalities resembling pseudoxanthoma elasticum in beta thalassemia and the sickling syndromes. Blood2002; 99: 30–35.
5.
DabbsTRSkjodtK.Prevalence of angioid streaks and other ocular complications of Paget’s disease of bone. Br J Ophthalmol1990; 74(10): 579–582.
6.
GibsonMJChaudhuriRRosenthalA.Angioid streaks in a case of beta thalassaemia major. Br J Ophthalmol1983; 67(1): 29–31.
7.
FingerRPCharbelIssaPLadewigMS, et al. Pseudoxanthoma elasticum: genetics, clinical manifestations and therapeutic approaches. Surv Ophthalmol2009; 54(2): 272–285.
8.
SchatzH.Other retinal pigment epithelial diseases. Int Ophthalmol Clin1975; 15(1): 181–197.
9.
KaracorluMKaracorluSOzdemirH, et al. Photodynamic therapy with verteporfin for choroidal neovascularization in patients with angioid streaks. Am J Ophthalmol2002; 134: 360–366.
10.
TeixeiraAMoraesNFarahME, et al. Choroidal neovascularization treated with intravitreal injection of bevacizumab (Avastin) in angioid streaks. Acta Ophthalmol Scand2006; 84(6): 835–836.
11.
DeutmanAFKovacsB.Argon laser treatment in complications of angioid streaks. Am J Ophthalmol1979; 88: 12–17.
12.
BrancatoRMenchiniUPeceA, et al. Laser treatment of macular subretinal neovascularizations in angioid streaks. Ophthalmologica1987; 195(2): 84–87.
13.
PeceAAvanzaPGalliL, et al. Laser photocoagulation of choroidal neovascularization in angioid streaks. Retina1997; 17: 12–16.
14.
MenchiniUVirgiliGIntroiniU, et al. Outcome of choroidal neovascularization in angioid streaks after photodynamic therapy. Retina2004; 24(5): 763–771.
15.
LadasIDGeorgalasIRouvasAA, et al. Photodynamic therapy with verteporfin of choroidal neovascularization in angioid streaks: conventional versus early retreatment. Eur J Ophthalmol2005; 15(1): 69–73.
16.
BrowningACChungAKGhanchiF, et al. Verteporfin photodynamic therapy of choroidal neovascularization in angioid streaks: one-year results of a prospective case series. Ophthalmology2005; 112(7): 1227–1231.
17.
GliemMFingerRPFimmersR, et al. Treatment of choroidal neovascularization due to angioid streaks: a comprehensive review. Retina2013; 33(7): 1300–1314.
18.
SpaideRFSorensonJMarananL.Photodynamic therapy with verteporfin combined with intravitreal injection of triam-cinolone acetonide for choroidal neovascularization. Ophthalmology2005; 112: 301–304.
19.
ArtunayOYuzbasiogluERasierR, et al. Combination treatment with intravitreal injection of ranibizumab and reduced fluence photodynamic therapy for choroidal neovascularization secondary to angioid streaks: preliminary clinical results of 12-month follow-up. Retina2011; 31(7): 1279–1286.
20.
MimounGTilleulJLeysA, et al. Intravitreal ranibizumab for choroidal neovascularization in angioid streaks. Am J Ophthalmol2010; 150: 692–700.
21.
El MatriLKortFBouraouiR, et al. Intravitreal bevacizumab for the treatment of choroidal neovascularization secondary to angioid streaks: one year of follow-up. Acta Ophthalmol2011; 89(7): 641–646.
22.
FingerRPCharbel IssaPHendigD, et al. Monthly ranibizumab for choroidal neovascularizations secondary to angioid streaks in pseudoxanthoma elasticum: a one-year prospective study. Am J Ophthalmol2011; 152(4): 695–703.
23.
LadasIDKotsolisAILadasDS, et al. Intravitreal ranibizumab treatment of macular choroidal neovascularization secondary to angioid streaks: one-year results of a prospective study. Retina2013; 30(8): 1185–1189.
24.
HeierJSBrownDMChongV, et al. VIEW 1 and VIEW 2 study groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology2012; 119(12): 2537–2548.
25.
KumarNMarsigliaMMrejenS, et al. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatment with ranibizumab in patients with neovascular age-related macular degeneration. Retina2013; 33(8): 1605–1612.
26.
DespreauxRCohenSYSemounO, et al. Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice. Graefes Arch Clin Exp Ophthalmol2016; 254(4): 639–644.
27.
EsenESizmazSDemircanN.Intravitreal aflibercept for management of subfoveal choroidal neovascularization secondary to angioid streaks. Indian J Ophthalmol2015; 63(7): 616–618.
28.
Vaz-PereiraSCollaçoLDe SalvoG, et al. Intravitreal aflibercept for choroidal neovascularisation in angioid streaks. Eye (Lond)2015; 29: 1236–1238.
29.
TetikogluMSagdikHMAktasS, et al. Intravitreal aflibercept for refractory choroidal neovascularization secondary to angioid streaks. Eye (Lond)2016; 30(6): 894–895.
30.
ChassaingNMartinLCalvasP, et al. An update on the clinical phenotype in patients with pseudoxanthoma elasticum. Front Genet2013; 4: 14.
31.
FungATKumarNVanceSK, et al. Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study). Eye (Lond)2012; 26(9): 1181–1187.
32.
EbranJMMimounGCohenSY, et al. Treatment with ranibizumab for choroidal neovascularization secondary to a pseudoxanthoma elasticum: results of the French observational study PiXEL. J Fr Ophtalmol2016; 39(4): 370–375.
33.
DiagoT.Treat and extend regimen with aflibercept for choroidal neovascularization in angioid streaks. Eye (Lond)2016; 30: 637–639.
34.
TilleulJMimounGQuerquesG, et al. Intravitreal ranibizumab for choroidal neovascularization in angioid streaks. Four-year follow-up. Retina2016; 36: 483–491.
35.
ArcinueCAMaFBarteselliG, et al. One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration. Am J Ophthalmol2015; 159: 426–436.
36.
MuftuogluIKArcinueCATsaiFF, et al. Long-term results of pro re nata regimen of aflibercept treatment in persistent neovascular age-related macular degeneration. Am J Ophthalmol2016; 167: 1–9.
37.
YonekawaYAndreoliCMillerJB, et al. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol2013; 156(1): 29–35.
38.
SchachatAP.Switching antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. Am J Ophthalmol2013; 156(1): 1–2.
